Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Publishing Ltd
    British journal of dermatology 134 (1996), S. 0 
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Summary Humoral immune responses to Borrelia hurgdorferi (Bb) have been reported to occur in certain patients with circumscribed scleroderma (CS) (morphoea). Together with the isolation of spiro-chaetes from CS skin biopsies, this finding was taken to suggest Bb as the aetiological agent of CS. Since there is cellular immunoreactivity to Bb in patients with chronic Lyme borreliosis (LB). Bb-specific lymphocytic responses were tested in patients with CS. For this purpose, peripheral blood mononuclear cells from CS patients and. as controls, from patients with various manifestations of LB, and from healthy volunteers without any evidence of Bb infection, were exposed to Bb organisms for 5 days and then assayed for DNA synthesis. Stimulation indices (SI)〉 10 were scored positive. By performing lymphocyte proliferation tests we found: (i) that not only patients with various manifestations of LB but also a considerable percentage of seropositive (five of 13 = 38%) and seronegative (six of 26 = 23%) CS patients exhibit an elevated Bb-induced lymphocyte proliferation; (ii) that the magnitude of the cellular response seen in CS patients is comparable to that encountered in patients with established Bb manifestations; and (iii) that, within a given patient, antibiotic therapy can result in a significant reduction of this response. These results support a causative role of Bb in at least some CS patients. Bb-induced lymphocyte responses were also seen in both seropositive and seronegative erythema chronicum migrans patients. These findings show that the pattern of Bb-specific immune responses is more complex than previously thought, and underscore the importance of lymphocyte function assays in evaluating the diagnosis of potential Bb infection in seronegative patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1439-0973
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Zum Vergleich der klinischen Wirksamkeit und Sicherheit einer Behandlung des Erythema chronicum migrans mit Phenoxymethylpenicillin und Minocyclin wurde eine offene, randomisierte klinische Studie durchgeführt. 60 ambulante Patienten (25 Männer, 35 Frauen im Alter von 19–80 Jahren) mit Erythema migrans erhielten nach einem Randomisierungsschema entweder eine Behandlung mit Phenoxymethylpenicillin (4,5 Mio IE/Tag für 21 Tage; Gruppe A) oder mit Minocyclin (200 mg/Tag für 21 Tage; Gruppe B). Die beiden Patientengruppen waren hinsichtlich Alter und Geschlecht homogen. Alle Patienten wurden bis zu 12 Monate nach Therapiebeginn nachkontrolliert. In beiden Gruppen kam es innerhalb der Behandlungszeit zur Abheilung des Erythema migrans. Alle 39 über 21 Tage behandelten Patienten zeigten bis zu 12 Monate nach Therapiebeginn keine Zeichen von Spätmanifestationen der Lyme-Borreliose. Hingegen wurden bei zwei Patienten, die vorzeitig die Therapie abgebrochen hatten (ein mit Penicillin behandelter Patient nach 14 Tagen und ein mit Minocyclin behandelter Patient nach 4 Tagen Therapiedauer), während des Beobachtungszeitraumes Müdigkeit und Konzentrationsstörungen beobachtet. 21 Patienten mußten aufgrund eines Therapieabbruches von der Evaluierung ausgeschlossen werden. Vor Therapiebeginn wurde eine humorale Immunantwort gegenBorrelia burgdorferi bei 6/21 Patienten der Penicillin-Gruppe und bei 3/18 Patienten der Minocyclin-Gruppe nachgewiesen. Ein Jahr nach Studienbeginn waren 8/39 Patienten seropositiv. Die Ergebnisse zeigen, daß Phenoxymethylpenicillin und Minocyclin in der Behandlung des Erythema migrans als gleichwertig einzuschätzen sind, wobei die Therapiedauer über 21 Tage als wesentlich für den Langzeittherapieerfolg angesehen wird.
    Notes: Summary An open, randomized, prospective study was carried out to compare the clinical efficacy and safety of phenoxymethylpenicillin with that of minocycline in the treatment of erythema migrans. Sixty patients (minocycline 30, penicillin 30) were enrolled in the study. The two groups of patients were statistically homogeneous regarding age and sex distribution. IgG and IgM antibodies againstBorrelia burgdorferi were determined by ELISA before and after treatment and 1 year thereafter. Thirty-nine patients completed the study. All these patients (penicillin 21, minocycline 18) who received a 21-day course of treatment were free of clinical symptoms of late Lyme borreliosis after 1 year. Serum antibodies againstB. burgdorferi could be detected before treatment in 6/21 patients treated with penicillin and 3/18 patients treated with minocycline. After 1 year 8/39 patients were seropositive without any evidence of ongoing disease. In the remaining 21 patients treatment could not be completed with the initial antibiotic due to side effects (penicillin 9/30, minocycline 12/30). One patient, who stopped penicillin treatment at day 14 and one patient who stopped minocycline at day 4, developed fatigue and memory impairment within the observation period. A 3-week course of treatment with penicillin or minocycline is equally effective in treating patients with erythema migrans and preventing late symptoms of Lyme borreliosis.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...